Stock Movers Constellation Energy Falls, McCormick Slides, Apellis Pharmaceuticals Gains
Mar 31, 2026
A rundown of heavy market moves in energy, consumer goods and biotech. Discussion of an energy company’s earnings forecast miss and its stock drop. Coverage of a major food-business merger that rattled a seasoning maker’s shares. Report on a biotech takeover that sent its stock sharply higher.
AI Snips
Chapters
Transcript
Episode notes
Constellation Energy EPS Miss Drives Big Drop
- Constellation Energy plunged about 8.7% after forecasting full-year EPS below analyst estimates.
- Barclays noted mixed outlook: nuclear contracting progressing but EPS guidance missed consensus, pushing CEG toward one of the worst S&P 500 performers today.
McCormick Drop After Unilever Food Deal
- McCormick shares fell about 5.4% after agreeing to combine with Unilever's food business in a $44.8 billion deal.
- Vital Knowledge highlighted investor aversion to food-focused staples and M&A risks despite McCormick's decent results, sending MKC to lows not seen since 2018.
Apellis Soars On Biogen Acquisition
- Apellis Pharmaceuticals surged about 137% intraday after Biogen agreed to acquire it for roughly $5.6 billion.
- RBC said the deal rescues struggling Apellis shares and boosts Biogen's kidney, rare disease, and immunology pipelines with two approved drugs.